Important notification
24.07.2023 To the attention of manufacturers, authorised representatives, economic operators and all interested stakeholders Please be informed that on 18 […]
Important notification
21.07.2023 To the attention of all interested parties (importers, distributors, users – health units and patients) The NAMMDR warns all […]
Press release
21.07.2023 To the attention of interested persons Start of a review concerning the conduct of studies at Synapse Labs Pvt. […]
Important notification
20.07.2023 To the attention of interested persons List of training providers with the topic of legislation in the field of […]
Press release
19.07.2023 To the attention of interested persons Reflection paper on the use of artificial intelligence in the lifecycle of medicines […]
Press release
11.07.2023 To the attention of interested persons EMA statement on ongoing review of GLP-1 receptor agonists download document …
Press release
27.06.2023 To the attention of interested persons Withdrawal of application for the marketing authorisation of Lagevrio (molnupiravir) download document …
Press release
23.06.2023 To the attention of interested persons Refusal of the marketing authorisation for Albrioza (sodium phenylbutyrate / ursodoxicoltaurine) download document […]
Important notification
22.06.2023 To the attention of manufacturers, authorised representatives, economic operators and all stakeholders Please be informed that Commission Implementing Regulation […]
Important notification
07.06.2023 To the attention of all importers, distributors and users of medical devices The NAMMDR warns all importers and distributors […]